Patents Assigned to Genentech, Inc.
-
Patent number: 11659990Abstract: A method to self-test vision of a user for use with a handheld vision tester includes receiving image data of the user's face, determining dimensions of the user's face based on the received image data, computing a user viewing distance based on the determined dimensions, displaying a vision test based on the computed user viewing distance, receiving user input responses to the vision test, and outputting results of the vision test from the user input responses.Type: GrantFiled: July 21, 2020Date of Patent: May 30, 2023Assignee: GENENTECH, INC.Inventors: Michael Bartlett, Yi-Zhong Wang
-
Patent number: 11661424Abstract: Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3?-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4?]bipyridinyl-2?-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided.Type: GrantFiled: November 23, 2020Date of Patent: May 30, 2023Assignee: Genentech, Inc.Inventors: Danial Beaudry, Theresa Cravillion, Francis Gosselin, Ngiap-Kie Lim, Sushant Malhotra, Qingping Tian, Haiming Zhang, Alexander Gmehling, Alec Fettes, Stephan Bachmann
-
Publication number: 20230160907Abstract: The presently disclosed subject matter provides methods for determining the propensity of a polypeptide or a fragment thereof, e.g., an antibody or a fragment thereof, to elicit production of anti-drug antibodies (ADAs) and kits for performing such methods.Type: ApplicationFiled: January 11, 2023Publication date: May 25, 2023Applicant: GENENTECH, INC.Inventors: Lynn Anne Kamen, Rachel Ann Melendez, Shan Chung
-
Publication number: 20230159555Abstract: Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.Type: ApplicationFiled: July 21, 2022Publication date: May 25, 2023Applicant: Genentech, Inc.Inventors: Paul GIBBONS, Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Bing-Yan ZHU, Huifen CHEN
-
Publication number: 20230159886Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.Type: ApplicationFiled: September 27, 2022Publication date: May 25, 2023Applicant: Genentech, Inc.Inventors: Masaru Ken SHIRATORI, Robert David KISS, Hardayal PRASHAD, Raquel IVERSON, Justin BOURRET, Michael KIM, Salim CHARANIYA
-
Patent number: 11655245Abstract: The invention relates to methods of using compounds formula I: and pharmaceutically acceptable salts thereof wherein A, X, R1, R4 and n are as defined herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.Type: GrantFiled: June 16, 2020Date of Patent: May 23, 2023Assignee: Genentech, Inc.Inventors: Jack Alexander Terrett, Huifen Chen, Lea Constantineau-Forget, Robin Larouche-Gauthier, Luce Lépissier, Francis Beaumier, Martin Déry, Chantal Grand-Maître, Claudio Sturino, Matthew Volgraf, Elisia Villemure
-
Patent number: 11655305Abstract: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.Type: GrantFiled: June 2, 2020Date of Patent: May 23, 2023Assignee: Genentech, Inc.Inventors: Virginia Paton, Anne Blackwood Chirchir, Pam Klein
-
Patent number: 11654105Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.Type: GrantFiled: August 22, 2022Date of Patent: May 23, 2023Assignees: Genentech, Inc., Hoffmann-La RocheInventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
-
Publication number: 20230151103Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.Type: ApplicationFiled: August 12, 2022Publication date: May 18, 2023Applicant: Genentech, Inc.Inventors: Priti HEGDE, Luciana MOLINERO, Sanjeev MARIATHASAN, Shannon TURLEY, Jillian ASTARITA, Rafael CUBAS, Yagai YANG
-
Publication number: 20230154626Abstract: Systems and methods described herein improve outcomes of subjects with lymphoma. Subjects with lymphoma may be able to avoid conventional treatments that have a high probability of leading to an adverse effect in the subject. Systems and methods allow for a more accurate prediction of subjects who cannot tolerate a particular treatment. Methods may include accessing an input data set that includes multiple input data values pertaining to a particular subject with lymphoma. The method may further include inputting the input data set into a machine-learning model to generate a score corresponding to the degree to which the particular subject will tolerate a particular treatment. The method may include outputting a prediction of the tolerance of the particular subject to the particular treatment using the generated score.Type: ApplicationFiled: January 19, 2023Publication date: May 18, 2023Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.Inventors: Tina Geritz Nielsen, Joseph Nathaniel Paulson, Daniel Jay Schneider, Edward Jean Bataillard, Carl Wilson Harris, III, Carsten Henneges, Yoonha Choi
-
Publication number: 20230149395Abstract: Provided herein are methods of treating Relapsing Multiple Sclerosis (RMS) in a subject in need thereof, by administering to the subject about 200 mg of fenebrutinib twice daily, or an equivalent amount of a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 1, 2021Publication date: May 18, 2023Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Hideki GARREN, Edmond Huatung TENG, Aurelien VIACCOZ, Hans-Christian VON BUEDINGEN
-
Patent number: 11649241Abstract: Compounds of Formula I and methods of use as Janus kinase inhibitors are described herein.Type: GrantFiled: February 12, 2021Date of Patent: May 16, 2023Assignee: Genentech, Inc.Inventors: Mark Zak, F. Anthony Romero, Po-wai Yuen, Emily J. Hanan
-
Patent number: 11648317Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.Type: GrantFiled: April 12, 2019Date of Patent: May 16, 2023Assignee: Genentech, Inc.Inventors: Ankit R. Patel, Jun Liu
-
Patent number: 11648315Abstract: The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.Type: GrantFiled: March 23, 2020Date of Patent: May 16, 2023Assignee: Genentech, Inc.Inventors: Thomas Pillow, Andrew G. Polson, Bing Zheng
-
Publication number: 20230143532Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.Type: ApplicationFiled: October 7, 2022Publication date: May 11, 2023Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical ResearchInventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
-
Patent number: 11643421Abstract: The present disclosure provides for methods for preparing tricyclic PI3K inhibitor compounds in high yield and purity in aqueous solvent systems.Type: GrantFiled: December 8, 2020Date of Patent: May 9, 2023Assignee: GENENTECH, INC.Inventors: Andreas Stumpf, Remy Angelaud, Andrew McClory, Herbert Yajima, Chudi Ndubaku, Alan Olivero
-
Publication number: 20230132508Abstract: The present disclosure relates to methods of measuring and analyzing phosphorylation sites in the tau protein and determining correlations with other biomarkers of Alzheimer's disease and tauopathies.Type: ApplicationFiled: March 31, 2021Publication date: May 4, 2023Applicants: Genentech Inc., Washington UniversityInventors: Kristin Ruth Wildsmith, Balazs Toth, Randall Bateman, Nicolas Barthelemy
-
Patent number: 11639395Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.Type: GrantFiled: November 2, 2020Date of Patent: May 2, 2023Assignee: Genentech, Inc.Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
-
Patent number: 11638756Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.Type: GrantFiled: August 22, 2022Date of Patent: May 2, 2023Assignees: Genentech, Inc., Hoffman-La Roche Inc.Inventors: Mark C. Benyunes, Graham Alexander Ross
-
Publication number: 20230125415Abstract: A method of treating pneumonia in a patient is disclosed comprising administering an effective amount of an IL-6 antagonist to a patient identified as having elevated ferritin level. Also disclosed is a method of achieving an improved clinical response in a patient with pneumonia comprising: a. measuring ferritin level in the patient, and b. administering an effective amount of an IL-6 antagonist to the patient identified as having an elevated ferritin level. The improved clinical response achieved includes: no death by Day 28, not mechanically ventilated by Day 28 (wherein the patient was not mechanically ventilated at baseline), better ordinal score at Day 28, and/or reduced time to hospital discharge within 28 days, compared to the clinical response in a patient with pneumonia and ferritin level that is not elevated.Type: ApplicationFiled: March 19, 2021Publication date: April 27, 2023Applicant: Genentech, Inc.Inventors: Min Bao, Fang Cai, Jennifer Tom, Larry Wilse Tsai